Due to the critical role of BCR::ABL1 in the pathogenesis of CML, tyrosine kinase inhibitors (TKIs) have become the cornerstone of modern CML therapy (3) with molecular response to TKI treatment serving as the key determinant of long-term prognosis in CML (4). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.